{"entity":{"id":"nct07306273","kind":"trial","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","summary":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy is a phase 2, interventional study registered as NCT07306273 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2025-12-15 and due to reach its primary completion in 2027-08-01. Interventions recorded: Irreversible electroporation; Dual-Function Antibody PD-1/CTLA-4. Conditions listed: Pancreatic Adenocarcinoma Locally Advanced. Primary outcome: Overall Survival. Pancreatic eligibility wording from the registry: \"* Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records indicating locally advanced pancreatic cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07306273","url":"https://clinicaltrials.gov/study/NCT07306273"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["irreversible-electroporation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07306273","phase":"2","setting":"A Single-Arm, Open-Label Clinical Study of Irreversible Electroporation(IRE) Combined With the Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) for the Treatment of Locally Advanced Pancreatic Cancer Following Failure of First-Line AG Therapy","sponsor":"Ruijin Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07306273/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}